Press releases
June 3, 2024
BIOPHTA 6.5 million Euros Seed Funding
Paris, June 3, 2024
BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development.
This funding round was led by leading European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital – as well as one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.
To see our most recent news,
Read more
news from us
-
Articles July 5, 2024HTL Biotechnology Secures Medical Device Registration in China
Sodium DNA Raw Material Main Document (Polynucleotides) registered as a medical device (number M2024199-000) in China.
-
Articles June 21, 2024HTL Biotechnology at CPHI China 2024
CPHI China is one of Asia’s leading Pharma events for trading and networking with 3,500+ exhibitors and 90,000+ professionals from the pharmaceutical industry,
-
Articles June 13, 2024Discover our Quality Policy
At HTL Biotechnology, we believe in going beyond together to achieve the highest quality standards.